<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">CB1 Cannabinoid Receptor Neurons</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>CB1 Cannabinoid Receptor Neurons</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>
<table class="infobox infobox-cell">
<tr>
<th class="infobox-header" colspan="2">CB1 Cannabinoid Receptor Neurons</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>CB1 Cannabinoid Receptor Neurons</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Cell Type</td>
</tr>
</table>
The cannabinoid type 1 (CB1) receptor represents the most abundant G protein-coupled receptor in the mammalian brain, serving as the primary molecular target for the psychoactive effects of delta-9-tetrahydrocannabinol (THC) and the central component of the endocannabinoid system. [@piomelli2003] CB1 receptors are expressed at high density on presynaptic terminals throughout the central nervous system, where they regulate neurotransmitter release through a process termed retrograde signaling. [@marsicano2003] This modulatory system plays fundamental roles in synaptic plasticity, learning and memory, motor control, appetite, pain perception, and emotional regulation.
The endocannabinoid system comprises CB1 receptors, their endogenous ligands (anandamide and 2-arachidonoylglycerol), and the enzymatic machinery for ligand synthesis and degradation. [@bisogno2008] This signaling system is dynamically regulated by neuronal activity and participates in various forms of plasticity including long-term depression (LTD), long-term potentiation (LTP), and homeostatic adaptations to chronic activity changes. [@kano2009] Understanding CB1 receptor function provides insight into both normal brain operation and the pathogenesis of neurodegenerative disorders including Alzheimer's disease, Parkinson's disease, and Huntington's disease. [@hu2020]
The CB1 receptor is a Class A G protein-coupled receptor with the characteristic seven transmembrane domain architecture. The receptor binds multiple ligand classes: phytocannabinoids from cannabis (including THC and CBD), synthetic cannabinoids, and endogenous endocannabinoids. [@piomelli2003] The receptor exhibits constitutive activity in the absence of agonists, and this basal signaling can be modulated by inverse agonists and allosteric modulators.
CB1 receptor signaling is primarily mediated through Gi/o proteins, which inhibit adenylate cyclase activity and reduce intracellular cAMP levels. This coupling leads to several downstream effects including activation of inwardly rectifying potassium channels (GIRK), inhibition of voltage-gated calcium channels (particularly N-type and P/Q-type), and activation of MAPK signaling pathways. [@kano2009] The diversity of signaling pathways engaged by CB1 receptors allows context-dependent modulation of cellular function.
CB1 receptor expression is highly heterogeneous across brain regions, with the highest densities in the basal ganglia (globus pallidus, substantia nigra pars reticulata), cerebellum (Purkinje cell layer), and hippocampus (CA pyramidal cells, dentate gyrus granule cells). [@katona2008] Moderate expression is found in the neocortex, particularly Layer 5 pyramidal neurons, and in the hypothalamus.
Within individual neurons, CB1 receptors are predominantly localized to presynaptic terminals, where they reside on both glutamatergic and GABAergic nerve endings. The presynaptic localization enables CB1 receptors to regulate neurotransmitter release in a retrograde manner: postsynaptic neurons release endocannabinoids that activate presynaptic CB1 receptors, thereby suppressing further transmitter release. [@wilson2002] This unique signaling architecture allows precise, temporally restricted modulation of synaptic strength.
The defining feature of endocannabinoid signaling is its retrograde nature: the signals originate from postsynaptic neurons and act on presynaptic receptors. [@marsicano2003] This process is engaged by strong synaptic activation or depolarization, which triggers synthesis and release of endocannabinoids from the postsynaptic spine. The two major endocannabinoids—anandamide (N-arachidonoylethanolamine, AEA) and 2-arachidonoylglycerol (2-AG)—are synthesized through distinct pathways and have different pharmacological properties. [@bisogno2008]
2-AG is the more abundant endocannabinoid in the brain and acts as a full agonist at CB1 receptors. Its synthesis is triggered by Gq-coupled receptor activation or by rises in intracellular calcium, both of which activate diacylglycerol lipase (DGL), the enzyme that produces 2-AG from DAG. Anandamide acts as a partial agonist at CB1 receptors and is synthesized through a distinct pathway involving N-acetyltransferase and phospholipase D. [@bisogno2008]
Endocannabinoid signaling participates in multiple forms of synaptic plasticity throughout the brain. Depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE) are rapid, transient forms of plasticity that depend on postsynaptic depolarization triggering endocannabinoid release. These forms of plasticity allow neurons to temporarily suppress specific synaptic inputs based on recent activity patterns. [@kano2009]
Long-term depression (LTD) at CB1 receptor-expressing synapses represents a longer-lasting form of plasticity. This LTD is expressed presynaptically as a reduction in neurotransmitter release probability and requires sustained CB1 receptor activation. Endocannabinoid-mediated LTD has been described at parallel fiber-Purkinje cell synapses in the cerebellum, at glutamatergic synapses in the hippocampus, and at striatal medium spiny neuron synapses. [@agarwal2020]
The basal ganglia contain among the highest densities of CB1 receptors in the brain, reflecting the critical role of endocannabinoid signaling in motor control. [@katona2008] In the direct pathway, CB1 receptor activation reduces GABA release from striatal medium spiny neurons, modulating the disinhibition of thalamocortical neurons that enables movement initiation. In the indirect pathway, CB1 receptors regulate the inhibitory outputs from the globus pallidus and substantia nigra pars reticulata.
Endocannabinoid signaling contributes to motor learning and habit formation by modulating plasticity at corticostriatal synapses. The tonically active endocannabinoid system allows fine-tuning of basal ganglia output based on behavioral context. [@gomez2020] Dysregulation of this system contributes to the motor symptoms of Parkinson's disease and the hyperkinetic movements of Huntington's disease.
The hippocampus expresses high levels of CB1 receptors, particularly on GABAergic interneurons that regulate the activity of CA1 pyramidal neurons. [@kano2009] This architecture enables endocannabinoid signaling to modulate hippocampal network oscillations and synaptic plasticity relevant to memory formation. CB1 receptor activation generally impairs memory consolidation while sparing retrieval, likely reflecting the role of CB1 receptors in regulating hippocampal encoding processes.
In the prefrontal cortex, CB1 receptors modulate working memory and executive function by regulating the balance of excitation and inhibition in Layer 5 pyramidal neuron circuits. [@hu2020] The density of CB1 receptors in prefrontal cortex is lower than in hippocampus or basal ganglia, but this modulatory system nonetheless influences prefrontal-dependent cognitive operations.
The mesolimbic dopamine system, which mediates reward processing and motivation, is profoundly influenced by endocannabinoid signaling. CB1 receptors are expressed on glutamatergic terminals from the prefrontal cortex and on dopaminergic terminals in the nucleus accumbens, allowing endocannabinoids to regulate both the input to and output from reward circuits. [@katona2008]
Endocannabinoid signaling in the ventral tegmental area and nucleus accumbens contributes to reward learning and the reinforcing effects of both natural rewards and drugs of abuse. CB1 receptor activation enhances food intake, and CB1 antagonists have been developed as anti-obesity agents. The role of endocannabinoid signaling in reward processing has implications for understanding addiction and anhedonia in neurodegenerative diseases.
Endocannabinoid signaling is altered in Alzheimer's disease, with complex patterns of CB1 receptor upregulation in early stages followed by downregulation in advanced disease. [@hu2020] These changes may represent compensatory responses to neurotransmitter system dysfunction or may contribute to disease progression through loss of neuroprotective signaling.
CB1 receptor activation exerts several potentially beneficial effects in Alzheimer's disease models: reduction of amyloid-beta production through APP processing modulation, anti-inflammatory effects that limit microglial activation, and protection against excitotoxicity. [@valdeolivas2012] However, chronic CB1 receptor activation may also impair memory function, complicating the therapeutic potential of cannabinoid-based approaches.
Neuroinflammation in Alzheimer's disease involves microglial activation and elevated pro-inflammatory cytokines that drive disease progression. The endocannabinoid system modulates neuroinflammation through both CB1 and CB2 receptors, with CB2 receptor activation particularly implicated in limiting microglial pro-inflammatory responses. [@stella2010] Therapeutic strategies targeting the endocannabinoid system must balance anti-inflammatory benefits against potential memory-impairing effects.
Parkinson's disease is associated with substantial alterations in endocannabinoid signaling, particularly in the basal ganglia. Endocannabinoid levels are elevated in the basal ganglia of parkinsonian patients and animal models, likely reflecting compensatory changes in response to dopaminergic denervation. [@gomez2020] This elevation may contribute to hypokinetic symptoms by over-activating CB1 receptors that reduce movement-promoting outputs.
CB1 receptor antagonists and inverse agonists can ameliorate parkinsonian symptoms in animal models, suggesting that excessive endocannabinoid tone contributes to motor impairment. [@gomez2020] However, clinical trials of CB1 antagonists in Parkinson's disease have yielded mixed results, likely reflecting the complex role of endocannabinoid signaling in basal ganglia function and the need to target specific brain regions or patient subgroups.
Beyond motor symptoms, endocannabinoid dysfunction may contribute to non-motor features of Parkinson's disease including depression, anxiety, and sleep disorders. The role of CB1 receptors in mood regulation suggests that endocannabinoid-targeted approaches may address these disabling non-motor symptoms.
Huntington's disease is associated with early and profound loss of CB1 receptors in the basal ganglia, even before the onset of motor symptoms. This reduction reflects the vulnerability of medium spiny neurons that express high levels of CB1 receptors, and contributes to the hyperkinetic movements (chorea) characteristic of the disease. [@price2009]
The loss of CB1 receptor signaling in Huntington's disease has several consequences: disinhibition of striatal outputs that contributes to chorea, impaired synaptic plasticity at corticostriatal synapses, and failure of neuroprotective signaling. [@fernandezruiz2005] CB1 receptor agonists can reduce chorea in animal models but may also impair cognition, creating therapeutic challenges.
Emerging evidence suggests that endocannabinoid signaling is dysregulated in ALS, with both CB1 and CB2 receptors implicated in disease pathogenesis. CB1 receptor activation can protect motor neurons from excitotoxicity and oxidative stress in cellular models, suggesting potential therapeutic benefit. [@lorenz2021] However, the role of CB1 receptors in ALS is complicated by their expression on non-neuronal cells including astrocytes and microglia.
Phytocannabinoids from cannabis (THC, CBD) and synthetic cannabinoid derivatives have been explored for neurodegenerative disease treatment. CBD lacks psychoactive effects but exhibits anti-inflammatory, neuroprotective, and antioxidant properties that may benefit multiple conditions. [@valdeolivas2012] THC provides stronger CB1 activation but produces psychoactive effects and may impair cognition at higher doses.
Clinical trials of cannabinoid-based therapies in neurodegenerative diseases have yielded mixed results. Sativex (THC/CBD oromucosal spray) has been studied in ALS and showed some benefit for spasticity. CBD has been explored in Parkinson's disease psychosis with encouraging results. The variable effects likely reflect the complexity of endocannabinoid signaling and the need for better understanding of dose, timing, and patient selection.
CB2 receptors are expressed primarily on immune cells and microglia, making them attractive targets for modulating neuroinflammation without the psychoactive effects associated with CB1 activation. [@lorenz2021] CB2 receptor agonists reduce microglial activation and pro-inflammatory cytokine production in models of neurodegeneration.
The therapeutic potential of CB2-selective compounds lies in their ability to limit harmful neuroinflammation while preserving CB1-mediated synaptic function and cognition. Several CB2-selective agonists have entered clinical development for neurodegenerative conditions, with particular interest in Alzheimer's disease where neuroinflammation is a major contributor to pathology.
The following diagram shows the key molecular relationships involving CB1 Cannabinoid Receptor Neurons discovered through SciDEX knowledge graph analysis: